Rifampin Pharmacokinetics and Safety in Preterm and Term Infants

Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of <121 days postnatal age (PNA). We enrolled 27 infants; the median (range) gestational...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Smith, P. Brian, Cotten, C. Michael, Hudak, Mark L., Sullivan, Janice E., Poindexter, Brenda B., Cohen-Wolkowiez, Michael, Boakye-Agyeman, Felix, Lewandowski, Andrew, Anand, Ravinder, Benjamin, Daniel K., Laughon, Matthew M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535522/
https://ncbi.nlm.nih.gov/pubmed/30910891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00284-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars